CAPTRUST Financial Advisors
NAVB

CAPTRUST Financial Advisors’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

CAPTRUST Financial Advisors’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4
Closed – – 4646
2022
Q2 		$0 Hold
4
– – ﹤0.01% 5340
2022
Q1 		$0 Hold
4
– – ﹤0.01% 5329
2021
Q4 		$0 Sell
4
-150
-97% -$211 ﹤0.01% 5108
2021
Q3 		$0 Buy
154
+150
+3,750% +$252 ﹤0.01% 4939
2021
Q2 		$0 Hold
4
– – ﹤0.01% 4845
2021
Q1 		$0 Hold
4
– – ﹤0.01% 4631
2020
Q4 		$0 Hold
4
– – ﹤0.01% 3647
2020
Q3 		$0 Hold
4
– – ﹤0.01% 3387
2020
Q2 		$0 Buy
+4
New +$8 ﹤0.01% 2956
2019
Q4 		– Sell
-4
Closed – – 2047
2019
Q3 		$0 Buy
+4
New +$2 ﹤0.01% 2087
2018
Q3 		– Sell
-13
Closed – – 1764
2018
Q2 		$0 Buy
+13
New +$68 ﹤0.01% 1659

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CAPTRUST Financial Advisors's NAVB Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q3 2022, closing a stake of 4 shares.

CAPTRUST Financial Advisors first reported a position in NAVB in Q2 2018 and held it in 11 quarters. The position peaked at $0 in Q2 2022. 25 funds tracked by Wall St. Rank hold NAVB as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Navidea Biopharmaceuticals Inc. position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 4 Navidea Biopharmaceuticals Inc. shares in Q3 2022.
  • CAPTRUST Financial Advisors first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2018 and held it in 11 quarters.
  • CAPTRUST Financial Advisors's Navidea Biopharmaceuticals Inc. position peaked at $0 in Q2 2022.
  • 25 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.